DALIAN, China -- Chinese drugmaker Sinopharm has completed construction of a plant in Wuhan for mass production of a coronavirus vaccine candidate now under development, doubling its capacity to more than 200 million doses a year
Biotechnology
China's Sinopharm doubles output capacity for 2020 vaccine launch
Drugmaker's two plants can produce 200m doses as candidate moves through trials
Eighteen potential vaccines are in clinical trials, with seven being developed by Chinese pharmaceutical companies. © Reuters
Read Next
.JPG?width=178&fit=cover&gravity=faces&dpr=2&quality=medium&source=nar-cms&format=auto&height=100)
Latest on Biotechnology
